Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
Journal: Blood advances
Published: September 17, 2025
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 28, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Journal: EJHaem
Published: November 05, 2021
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Journal: British journal of haematology
Published: June 02, 2016
Genetically Engineered In Vitro Erythropoiesis.
Journal: International journal of stem cells
Published: February 23, 2016
Exogenous c-Myc Blocks Differentiation and Improves Expansion of Human Erythroblasts In vitro.
Journal: International journal of stem cells
Published: November 03, 2014
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).
Journal: Journal of hematology & oncology
Published: March 22, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026